Dive Brief:

潜水简介：

GSK on Monday said it has partnered with Chinese vaccine company Chongqing Zhifei Biological Products to co-promote its shingles vaccine Shingrix in China for at least the next three years.

葛兰素史克周一表示，至少在未来三年内，它已与中国疫苗公司重庆智飞生物制品有限公司合作，共同推广其带状疱疹疫苗Shingrix。

Zhifei, which GSK said is the largest vaccine company in China by revenue, will spend 2.5 billion pounds, or about $3 billion, to buy set volumes of Shingrix over the initial period of the deal. Starting Jan. 1, Zhifei will hold exclusive rights to import and distribute the shot in China.

葛兰素史克表示，Zhifei是中国最大的疫苗公司，在交易初期将花费25亿英镑（约30亿美元）购买一定数量的Shingrix。从1月1日开始，志飞将拥有在中国进口和分发镜头的独家权利。

The deal will help GSK market its top-selling product in the world’s second-largest pharmaceuticals market by spending. It also gives GSK right of first refusal to be Zhiefi’s partner for co-development and marketing of an respiratory syncytial virus vaccine for older adults in China.

该协议将帮助葛兰素史克通过支出在全球第二大药品市场上销售其最畅销产品。它还赋予葛兰素史克优先拒绝成为Zhiefi合作开发和销售中国老年人呼吸道合胞病毒疫苗的合作伙伴。

Dive Insight:

潜水洞察力：

GSK envisions the deal expanding Shingrix’s availability in China, where it said Zhifei oversees a network of more than 30,000 vaccination points. To support that distribution, GSK will co-promote the vaccine among doctors and at healthcare centers via awareness campaigns.

葛兰素史克预计该协议将扩大Shingrix在中国的可用性，并表示智菲负责监督3万多个疫苗接种点的网络。为了支持这种分布，葛兰素史克将通过宣传活动在医生和医疗中心共同推广疫苗。

Launched in 31 markets worldwide, Shingrix earned GSK sales over 800 million pounds in the second quarter. GSK aims to double annual revenue from the shot by 2026, to more than 4 billion pounds.

Shingrix在全球31个市场推出，第二季度获得GSK销售额超过8亿英镑。葛兰素史克的目标是到2026年将年收入增加一倍，达到40多亿英镑。

The partnership with Zhifei could also help it with its RSV vaccine Arexvy, which is approved in the U.S. but not yet in China.

与芝飞的合作关系也可以帮助它使用RSV疫苗Arexvy，该疫苗已在美国获得批准但尚未在中国获得批准。

Partnership with Zhifei could help speed Arexvy’s availability in China, should the shot win regulatory clearance there. GSK recently announced positive data from a study of Shingrix in Chinese adults aged 50 or older.

与智飞合作可以帮助加快Arexvy在中国的可用性，如果shot赢得监管部门的许可。葛兰素史克最近公布了一项针对50岁或以上中国成年人的Shingrix研究的积极数据。

Analysts predict the global RSV market will eventually reach billions of dollars in sales. Pfizer has also won approval of an RSV vaccine in the U.S., and Moderna is in the late stages of developing another.

分析师预测全球RSV市场最终将达到数十亿美元的销售额。辉瑞公司还在美国赢得了RSV疫苗的批准，Moderna正处于开发另一种疫苗的后期阶段。

Other Western drugmakers are continuing to expand in China. In April, for example, AstraZeneca said it would build a factory in China making inhalers to treat “smoker’s lung.”

其他西方制药商正在中国继续扩张。例如，四月，阿斯利康表示，它将在中国建立一家工厂，制造吸入器来治疗“吸烟者的肺”